Date of birth
Item
Date of birth
date
C0421451 (UMLS CUI [1])
Date of consent first parent
Item
Date of consent first parent
date
C0600634 (UMLS CUI [1])
Date of consent second parent
Item
Date of consent second parent (UK: not necessary)
date
C0600634 (UMLS CUI [1])
Item
Sex
integer
C0079399 (UMLS CUI [1])
Item
Consent for blood sample for pharmacogenetic analysis
integer
C0021430 (UMLS CUI [1])
Code List
Consent for blood sample for pharmacogenetic analysis
CL Item
"If yes, please document date of blood sample on page 39 „Pharmacogenetics“ (4)
Date of diagnosis
Item
Date of diagnosis
date
C2316983 (UMLS CUI [1])
Item
Is the planned infusion time in accordance with the above listed infusion time (taken from the protocol)?
integer
C0574032 (UMLS CUI [1])
Code List
Is the planned infusion time in accordance with the above listed infusion time (taken from the protocol)?
CL Item
Yes (protocol specific sampling sheets will be provided) (1)
CL Item
No, deviations are planned (one of three flexible standard sheets will be provided) (2)
CL Item
If no: administered infusion time: ≤ 0.5 h; > 0.5 h - < 12 h; ≥ 12 h (3)
Patient ≤ 17 years of age
Item
Patient ≤ 17 years of age
boolean
C0001779 (UMLS CUI [1])
Patient shall receive at least two cycles of doxorubicin
Item
Patient shall receive at least two cycles of doxorubicin
boolean
C0013089 (UMLS CUI [1])
Patient, parent(s) or legal representative has/have provided written informed consent to participate in the trial according to national regulations
Item
Patient, parent(s) or legal representative has/have provided written informed consent to participate in the trial according to national regulations
boolean
C0021430 (UMLS CUI [1])
Patient is enrolled in a national or European protocol
Item
Patient is enrolled in a national or European protocol - run by one of the study groups listed in the protocol - for treatment of Wilms tumours, neuroblastoma, soft tissue sarcoma, Ewing sarcoma or acute lymphatic leukaemia and is treated with doxorubicin according to that protocol Or Patient < 3 years enrolled or listed in any national or European study protocol for any paediatric malignancy. Treatment with doxorubicin has to be according to that protocol
boolean
C2348568 (UMLS CUI [1])
Life expectancy of at least 3 month
Item
Life expectancy of at least 3 month
boolean
C0023671 (UMLS CUI [1])
Karnofsky performance status of ≥ 70%
Item
Karnofsky performance status of ≥ 70%
boolean
C3829424 (UMLS CUI [1])
Additional blood withdrawal is acceptable for the patient
Item
Additional blood withdrawal is acceptable for the patient
boolean
C0005834 (UMLS CUI [1])
Item
Assent of patient, if patient is able to (if not able: please enter „N.A.“)
integer
C1879749 (UMLS CUI [1])
Code List
Assent of patient, if patient is able to (if not able: please enter „N.A.“)
CL Item
If assent is given: Date of patient assent (4)